CL2021002263A1 - Compuestos antibacterianos (solicitud divisional 202001147) - Google Patents

Compuestos antibacterianos (solicitud divisional 202001147)

Info

Publication number
CL2021002263A1
CL2021002263A1 CL2021002263A CL2021002263A CL2021002263A1 CL 2021002263 A1 CL2021002263 A1 CL 2021002263A1 CL 2021002263 A CL2021002263 A CL 2021002263A CL 2021002263 A CL2021002263 A CL 2021002263A CL 2021002263 A1 CL2021002263 A1 CL 2021002263A1
Authority
CL
Chile
Prior art keywords
divisional application
antibacterial compounds
compounds
enterobacteriaceae
diseases
Prior art date
Application number
CL2021002263A
Other languages
English (en)
Inventor
Paul Meo
Nawaz Khan
Cedric Charrier
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021002263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of CL2021002263A1 publication Critical patent/CL2021002263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Warehouses Or Storage Devices (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula general (II), a composiciones que comprenden estos compuestos y al uso de losmismos para la fabricación de medicamentos útiles en el tratamiento de enfermedades e infecciones bacterianas causadas por Enterobacteriaceae.
CL2021002263A 2017-11-03 2021-08-27 Compuestos antibacterianos (solicitud divisional 202001147) CL2021002263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds

Publications (1)

Publication Number Publication Date
CL2021002263A1 true CL2021002263A1 (es) 2022-04-01

Family

ID=60664899

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2020001147A CL2020001147A1 (es) 2017-11-03 2020-04-30 Compuestos antibacterianos
CL2021002263A CL2021002263A1 (es) 2017-11-03 2021-08-27 Compuestos antibacterianos (solicitud divisional 202001147)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2020001147A CL2020001147A1 (es) 2017-11-03 2020-04-30 Compuestos antibacterianos

Country Status (21)

Country Link
US (2) US11345694B2 (es)
EP (1) EP3704105A1 (es)
JP (2) JP7348897B2 (es)
KR (1) KR102470319B1 (es)
CN (1) CN111566099B (es)
AU (1) AU2018361828B2 (es)
BR (1) BR112020008531A2 (es)
CA (1) CA3081423A1 (es)
CL (2) CL2020001147A1 (es)
CO (1) CO2020005420A2 (es)
EA (1) EA202091118A1 (es)
GB (1) GB201718285D0 (es)
GE (1) GEP20237522B (es)
IL (1) IL274229B2 (es)
MA (1) MA50504A (es)
MX (2) MX2020004562A (es)
NZ (1) NZ764310A (es)
PE (2) PE20211390A1 (es)
SG (1) SG11202003717UA (es)
WO (1) WO2019086890A1 (es)
ZA (1) ZA202002093B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
CA3098428A1 (en) 2018-04-18 2019-10-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
EP4334299A1 (en) 2021-05-03 2024-03-13 Discuva Ltd. Process for the preparation of antibacterial compounds

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
AU2003249977A1 (en) 2002-07-05 2004-01-23 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
DK1692113T3 (en) 2003-11-14 2018-01-08 Lorus Therapeutics Inc ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
CA2556944C (en) * 2004-03-05 2012-10-09 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (en) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
KR101938368B1 (ko) 2011-07-13 2019-01-14 주식회사 티움바이오 Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
EP3708156A1 (en) * 2014-05-16 2020-09-16 Atriva Therapeutics GmbH Novel anti-infective strategy against influenza virus and s. aureus coinfections
MY186133A (en) 2015-03-02 2021-06-24 Rigel Pharmaceuticals Inc Tgf-? inhibitors
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
US10844051B2 (en) 2015-07-22 2020-11-24 The Royal Institution For The Advancement Of Learning/Mcgill University Substituted oxazoles for the treatment of cancer
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
IL274229B2 (en) 2023-05-01
US20210163460A1 (en) 2021-06-03
CO2020005420A2 (es) 2020-07-31
KR102470319B1 (ko) 2022-11-25
KR20200084875A (ko) 2020-07-13
MX2021010246A (es) 2021-09-21
JP2021501756A (ja) 2021-01-21
WO2019086890A1 (en) 2019-05-09
CN111566099B (zh) 2023-06-02
US11345694B2 (en) 2022-05-31
AU2018361828A1 (en) 2020-05-28
GB201718285D0 (en) 2017-12-20
PE20211390A1 (es) 2021-07-27
CN111566099A (zh) 2020-08-21
MX2020004562A (es) 2020-08-13
GEP20237522B (en) 2023-08-10
US20220372027A1 (en) 2022-11-24
AU2018361828B2 (en) 2023-05-18
CL2020001147A1 (es) 2020-08-14
ZA202002093B (en) 2023-11-29
NZ764310A (en) 2023-04-28
SG11202003717UA (en) 2020-05-28
JP7348897B2 (ja) 2023-09-21
IL274229B1 (en) 2023-01-01
EA202091118A1 (ru) 2020-08-06
IL274229A (en) 2020-06-30
JP2022025116A (ja) 2022-02-09
MA50504A (fr) 2020-09-09
CA3081423A1 (en) 2019-05-09
BR112020008531A2 (pt) 2020-10-20
PE20221006A1 (es) 2022-06-15
EP3704105A1 (en) 2020-09-09

Similar Documents

Publication Publication Date Title
CL2021002263A1 (es) Compuestos antibacterianos (solicitud divisional 202001147)
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
DOP2020000023A (es) Nuevos derivados de quinolina
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
UY37224A (es) Derivados aromáticos de sulfonamida
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
UY37789A (es) Nuevos derivados de azaquinolina
CO2019002624A2 (es) Compuestos antibióticos
CL2020000050A1 (es) Compuestos que afectan la producción de pigmentos y su uso para el tratamiento de enfermedades bacterianas.
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
UY38226A (es) Nuevos derivados de quinolina
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
BR112018011670A2 (pt) compostos antibacterianos
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CL2017002449A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112018069900A2 (pt) composição antimicrobiana, método de limpeza ou desinfecção de uma superfície e uso de um complexo fosfolipídico catiônico
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
BR112018076726A2 (pt) forma de cristal de compostos de tetraciclina substituídos por 9-aminometila e método de preparação da mesma
CL2019002203A1 (es) Nuevos compuestos heterocíclicos y sus usos en la prevención o el tratamiento de infecciones bacterianas.